Oxidized-LDL levels are changed during short-term serum glucose variations and lowered with statin treatment in early Type 2 diabetes: A study of endothelial function and microalbuminuria

Diabetic Medicine

Volumn 22, Issue 12, 2005, Pages 1647-1656

  Paniagua, J A ^a   Lopez Miranda J ^a   Perez Martinez P ^a   Marin C ^a   Vida, J M ^a   Fuentes, F ^a   Fernandez De La Puebla R A ^a   Perez Jimenez F ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Endothelium; Microalbuminuria; Oxidative stress; Statin; Type 2 diabetes

Indexed keywords

CERIVASTATIN; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; PROTHROMBIN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC OBESITY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM INJURY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; HYPERINSULINEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; PATIENT SELECTION; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ALBUMINURIA; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PYRIDINES; VASODILATION;

EID: 30044436869     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01703.x     Document Type: Article

References (55)

1. Balletshofer BM, Rittig K, Enderle MD, Volk A, Maerker E, Jacob S et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with Type 2 diabetes in association with insulin resistance. Circulation 2000; 101: 1780-1784.
2. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome. Diabetologia 1997; 140: 1286-1292.
3. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen G, Clausen P, Scharling H et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension and diabetes. Circulation 2004; 110: 32-35.
4. Cosentino F, Hishikawa K, Katusic ZS, Luscher TF. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 1997; 96: 25-28.
5. Ceriello A, Mercuri F, Quagliaro L, Assaloni R, Motz E, Tonutti L et al. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia 2001; 44: 834-838.
6. Napoli C, Lerman LO, de Nigris F, Loscalzo J, Ignarro LJ. Glycoxidized low-density lipoprotein downregulates endothelial nitricoxide synthase in human coronary cells. J Am Coll Cardiol 2002; 40: 1515-1522.
7. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993; 90: 6434-6438.
8. Pigott R, Dillon LP, Hemingway IH, Gearing AJ. Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun 1992; 187: 584-589.
9. Grahan A, Hogg N, Kalyaranaman B, O'Leary V, Darley-Usmar V, Moncada S. Peroxynitrite modification of low-density lipoprotein leads to recognition by the macrophage scavenger receptor. FEBS Lett 1993; 330: 181-185.
10. Cominacini L, Rigoni A, Pasini AF, Garbin U, Davoli A, Campagnola M et al. The binding of oxidized low density lipoprotein (Ox-LDL) to Ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through increased production of Superoxide. J Biol Chem 2001; 17: 13750-13755.
11. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457-462.
12. World Health Organization Expert Committee on Diabetes Mellitus. Definition diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. Report of a WHO Consultation. Geneva: World Health Organization 1999. Available from: http://www.who.int/ncd/dia_publications.htm (accessed December 2003).
13. Paniagua JA, Lopez-Miranda J, Escribano A, Berral FJ, Marin C, Bravo D et al. Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese Type 2 diabetes. Diabetes 2002; 51: 2596-2603.
14. Fuentes F, Lopez-Miranda J, Sanchez E, Sanchez F, Paez J, Paz-Rojas E et al. Mediterranean and low-fat diets improve endothelial function in hypercholesterolemic men. Ann Intern Med 2001; 9: 1115-1119.
15. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation for the brachial artery. A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-265.
16. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994; 24: 1468-1474.
17. Bennett PH, Haffner S, Kasiske BL, Keane WF, Mogensen CE, Parving HH et al. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kid Dis 1995; 25: 107-112.
18. Friedewald WT, Levy R, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
19. Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout J et al. Correlation between oxidized low density lipoprotein and von Willebrand factor in chronic renal failure. Thromb Haemost 1996; 76: 663-669.
20. ter Steege JC, Koster-Kamphuis L, van Straaten EA, Forget PP, Buurman WA. Nitrotyrosine in plasma of celiac disease patients as detected by a new sandwich ELISA. Free Radic Biol Med 1998; 25: 953-963.
21. Holvoet P, Ferez G, Zhao Z, Brouwers E, Bernar H, Collen D. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease. J Clin Invest 1995; 95: 2611-2619.
22. Shishehbor MH, Aviles RJ, Brennan ML, Fu X, Goormastic M, Pearce GL et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. J Am Med Assoc 2003; 289: 1675-1680.
23. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-1761.
24. Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest 2001; 108: 635-636.
25. Pennathur S, Wagner JD, Leeuwenburgh C, Litwak KN, Heinecke JW. A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. J Clin Invest 2001; 107: 853-860.
26. Di Carli MF, Janisse J, Grunberger G, Ager J. Role of chronic hyperglycemia in the pathogenesis of coronary microvascular dysfunction in diabetes. J Am Coll Cardiol 2003; 41: 1387-1393.
27. Iwakura K, Ito H, Ikushima M, Kawano S, Okamura A, Asano K et al. Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol 2003; 41: 1-7.
28. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
29. Title LM, Cummings PM, Giddens K, Nassar BA. Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamins C and E. J Am Coll Cardiol 2000; 36: 2185-2191.
30. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 2002; 106: 1211-1218.
31. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001; 103: 1955-1960.
32. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D et al. Oxidized LDL and malondialdehyde-modified LDL in patients with acute syndromes and stable coronary artery disease. Circulation 1998; 98: 1487-1494.
33. Hulthe J, Fagerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). Arterioscler Thromb Vasc Biol 2002; 22: 1162-1167.
34. Kopprasch S, Pietzsch J, Kuhlisch E, Fuecker K, Temelkova-Kurktschiev T, Hanefeld M et al. In vivo evidence for increased oxidation of circulating LDL in impaired glucose tolerance. Diabetes 2002; 51: 3102-3106.
35. Holvoet P, Kritchevsky SB, Tracy RP, Mertens A, Rubin SM, Butler J et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 2004; 53: 1068-1073.
36. John S, Schlaich M, Langenfeld M, Weihprecht H, Schmitz G, Weidinger G et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation 1998; 98: 211-216.
37. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997; 95: 76-82.
38. Raitakan OT, Pitkanen OP, Lehtimaki T, Lahdenpera S, Iida H, Yla-Herttuala S et al. In vivo low density lipoprotein oxidation relates to coronary reactivity in young men. J Am Coll Cardiol 1997; 30: 97-102.
39. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK et al. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001; 104; 376-379.
40. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endotheiial nitric oxide synthase. J Biol Chem 1997; 272: 31725-31729.
41. Navab M, Hama SY, Anantharamaiah GM, Hassan K, Hough GP, Watson AD et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 2000; 41: 1495-1508.
42. Spieker LE, Sudano I, Hurlimann D, Lerch PG, Lang MG, Binggeli C et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002; 105: 1399-1402.
43. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351: 88-92.
44. Chen NG, Azhar S, Abbasi F, Caramoni M, Reaven GM. The relationship between plasma glucose and insulin responses to oral glucose, LDL oxidation, and soluble intercellular adhesion molecule-1 in healthy volunteers. Atherosclerosis 2000; 152: 203-208.
45. Li D, Chen H, Romeo F, Sawamura T, Saldeen T, Mehta JL. Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1. J Pharmacol Exp Ther 2002; 302: 601-605.
46. Jilma B, Dallinger S, Hergovich N, Eichler HG, Richter V, Wagner OF. Effects of hyperinsulinemia on plasma levels of circulating adhesion molecules. J Clin Endocrinol Metab 2000; 85: 1748-1751.
47. Catalano C, Muscelli E, Quinones Galvan A, Baldi S, Masoni A, Gibb I et al. Effect of insulin on systemic and renal handling of albumin in nondiabetic and NIDDM subjects. Diabetes 1997; 46: 868-875.
48. Kuusisto J, Mykkanem L, Pyorala K, Laakso M. Hyperinsulinemic microalbuminuria. Circulation 1995; 91: 831-837.
49. Takemura T, Toshioka K, Aya N, Murakami K, Matsumoto A, Itakura H. Apolipoproteins in lipoprotein receptor in glomeruli in human kidney disease. Kidney Int 1993; 43: 918-927.
50. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260-269.
51. Danesh FR, Sadeghi MM, Amro N, Philips C, Zeng L, Lin S et al. 3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: implications for diabetic nephropathy. Proc Natl Acad Sci USA 2002; 99: 8301-8305.
52. Giustina A, Perini P, Desenzani P, Bossoni S, Ianniello P, Milani M et al. Long-term treatment UIT the dual antithromboxane agent picotinamide decreases microalbuminuria in normotensive Type 2 diabetic patients. Diabetes 1998; 47: 423-430.
53. Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 1998; 47: 793-800.
54. Sata M, Walsh K, Oxidized LDL. Activated Fas-mediated endothelial cell apoptosis. J Clin Invest 1998; 102: 1682-1689.
55. Camejo G, Olsson U, Hurt-Camejo E, Baharamian N, Bondjers G. The extracellular matrix on atherogenesis and diabetes-associated vascular disease. Atherosclerosis 2002; 3: 3-9.